T‐cell acute lymphoblastic leukemia following therapy of rhabdomyosarcoma

Chaim Kaplinsky*, Amos Frisch, Ian J. Cohen, Yacov Goshen, Lutfi Jaber, Isaar Yaniv, Batia Stark, Hanah Tamary, Rina Zaizov

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Multiple studies have documented an increased risk of secondary malignancies in patients receiving alkylating agents. Secondary leukemia following chemotherapy accounts for about 20% of all secondary neoplasms; most are acute nonlymphocytic. Secondary acute lymphoblastic leukemia has rarely been reported in either adult or childhood cancer. We report the development of acute T‐cell lymphoblastic leukemia in a child following successful treatment of a paravertebral embryonal rhabdomyosarcoma (ERS). Southern blot analysis of DNA extracted from the T‐cell lymphoblasts, using probes homologous to loci on the short arm of chromosome 11; P‐calcitonin, P40.1 and H‐ras, did not demonstrate the chromosomal loss of heterozygosity (LOH), a common feature of embryonal rhabdomyosarcoma. The data presented support the assumption that de novo leukemia emerged following treatment of the primary malignancy. © 1992 Wiley‐Liss, Inc.

Original languageEnglish
Pages (from-to)229-231
Number of pages3
JournalMedical and Pediatric Oncology
Issue number3
StatePublished - 1992
Externally publishedYes


  • T‐cell leukemia
  • alkylating agents
  • secondary acute lymphoblastic leukemia


Dive into the research topics of 'T‐cell acute lymphoblastic leukemia following therapy of rhabdomyosarcoma'. Together they form a unique fingerprint.

Cite this